ABSTRACT
This study examined the feasibility of Enzogenol® as a potential treatment modality for concussed individuals with residual symptoms in the chronic phase. Forty-two student-athletes with history of sport-related concussion were enrolled, comparing Enzogenol® versus placebo. Testing was conducted using virtual reality (VR) and electroencephalography (EEG), with neuropsychological (NP) tasks primarily used to induce cognitive challenges. After six weeks, the Enzogenol® group showed enhanced frontal-midline theta, and decreased parietal theta power, indicating reduced mental fatigue. Subjects enrolled in the Enzogenol® group also self-reported reduced mental fatigue and sleep problems. This suggests that Enzogenol® has the potential to improve brain functioning in the chronic phase of concussion.
Subject(s)
Athletic Injuries/drug therapy , Brain Concussion/drug therapy , Cognition/drug effects , Executive Function/drug effects , Flavonoids/therapeutic use , Postural Balance/drug effects , Quercetin/analogs & derivatives , Adolescent , Athletes , Athletic Injuries/diagnosis , Athletic Injuries/psychology , Brain Concussion/diagnosis , Brain Concussion/psychology , Electroencephalography , Female , Flavonoids/pharmacology , Humans , Male , Mental Fatigue/drug therapy , Mental Fatigue/psychology , Neuropsychological Tests , Quercetin/pharmacology , Quercetin/therapeutic use , Sleep/drug effects , Young AdultABSTRACT
A three-inch business card may seem like a minor tool in a nurse's pocket. But it can be a powerful means of developing respect for the profession inside and outside the hospital.
